MarketFriction

Dishman Carbogen Amcis Ltd

NSE DCAL · BSE 540701 · Pharmaceuticals
₹150.35 -4.52%
NSE close2026-10-01
52 week range128.50 - 306.00
Market cap₹2,528 Cr.
P/E139
Price band 20% Delivery 68.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales587651655524789682716708653720851678
Expenses526610592495642542564567504607688618
Operating Profit6141632914714015314114911316360
OPM %10%6%10%6%19%21%21%20%23%16%19%9%
Other Income564-448-422871516
Interest273331323749424342464337
Depreciation758085717272798184848991
Profit before tax-36-66-49-784227283931-1046-51
Tax %13%-10%42%0%21%83%-56%39%-114%24%53%13%
Net Profit-41-60-70-78335432365-1322-58
EPS in Rs-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,0311,7141,6952,0592,0441,9122,1412,4132,6162,7122,9322,901
Expenses8301,2611,2491,5071,5401,6381,8092,0812,3292,2432,3662,416
Operating Profit201452445552503274331332286469566485
OPM %20%26%26%27%25%14%15%14%11%17%19%17%
Other Income14264654391629-202245247
Interest5649495762485786120159174169
Depreciation69214211240283308308281311294339348
Profit before tax91216231309197-65-4-55-1221910515
Tax %12%33%33%32%20%154%-524%-45%26%83%7%
Net Profit80145155210159-16518-30-15339716
EPS in Rs9.5813.0310.10-10.531.15-1.90-9.790.216.221.03
Dividend Payout %0%0%0%2%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%9%7%0%
Compounded Profit Growth%21%140%-85%
Stock Price CAGR%-4%0%-40%
Return on Equity1%0%0%2%
Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital160.00323231313131313131
Reserves8634,8145,0755,3475,6845,6675,5185,7785,5965,8006,646
Borrowings8689501,0951,0421,3571,5891,8302,2092,3132,3893,076
Other Liabilities3348119678991,1211,0681,2551,4211,6311,7662,158
Total Liabilities2,0816,5747,1697,3218,1938,3568,6349,4399,5719,98711,911
Fixed Assets1,0124,8525,0665,0985,6785,6985,7736,1886,7247,0558,076
CWIP3071331511752344867801,043646467570
Investments1401961671911723242491029791
Other Assets7611,5501,7571,8812,0912,0001,7581,9592,0982,3683,174
Total Assets2,0816,5747,1697,3218,1938,3568,6349,4399,5719,98711,911
Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity203303226282585513355266379371491
Cash from Investing Activity-231-107-297-169-442-380-619-494-225-192-245
Cash from Financing Activity25-13778-102-98-11130250-22-102201
Net Cash Flow-35971146122-1332213277447
Free Cash Flow-3716422-26177147-101-35276156225
CFO/OP107%92%58%75%131%206%124%90%139%86%88%
Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60619679103808189689084
Inventory Days272473525496462402526568540655910
Days Payable17295201176226132158155149168189
Cash Conversion Cycle160439419399340350449502458577805
Working Capital Days-52354443-10-2-8-37-148-35-60
ROCE %5%6%4%0%1%1%0%2%3%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters59.32%59.32%59.32%59.32%59.32%59.32%59.32%59.32%59.32%59.32%59.32%59.32%
FIIs8.80%8.60%8.70%8.05%8.18%8.75%9.49%9.94%8.07%7.66%7.45%6.86%
DIIs3.51%3.68%2.36%1.47%1.22%1.42%1.26%1.27%1.37%1.27%1.63%2.06%
Public28.37%28.39%29.63%31.17%31.29%30.51%29.94%29.48%31.23%31.75%31.60%31.76%
No. of Shareholders56,27252,33650,65653,68355,28052,82250,75749,74449,45548,48149,00949,430

Fundamentals

Market Cap₹ 2,528 Cr.
Current Price₹ 161
Stock P/E139
Book Value₹ 426
ROCE3.14 %
ROE1.58 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)0%
Compounded Profit Growth (TTM)-85%
Consolidated figures.
Valuation
Market capRs 2,357 Cr
Enterprise valueRs 4,442 Cr
P/E (TTM)145.87x
Price to book0.35x
Price to sales0.81x
EV / EBITDA8.36x
EV / EBIT24.20x
EV / sales1.53x
Price to cash flow4.80x
Earnings yield0.69%
P/E, 3-year average537.40x
P/B, 3-year average0.52x
P/E, 5-year average411.87x
P/B, 5-year average0.48x
Profitability
Operating margin (excl. other income)19.29%
Operating margin (incl. other income)21.07%
EBITDA margin18.32%
Pre-tax margin0.52%
Net profit margin0.56%
Net margin, latest quarter-8.54%
ROE1.56%
ROCE3.11%
ROA0.89%
ROE, 3-year average-0.36%
ROCE, 3-year average1.76%
ROA, 3-year average-0.23%
ROE, 5-year average-0.25%
ROCE, 5-year average1.28%
ROA, 5-year average-0.16%
ROIC (approx.)1.95%
Tax rate7.10%
Other income / net worth0.78%
Growth
Sales growth (latest year)8.13%
Profit growth (latest year)2907.72%
Sales CAGR, 3 years6.71%
Sales CAGR, 5 years8.93%
Sales growth QoQ-20.41%
Profit growth QoQ-366.24%
Sales growth YoY (latest quarter)-4.29%
Profit growth YoY (latest quarter)-347.24%
Per share
EPS (TTM)Rs 1.03
EPS (latest year)Rs 6.22
EPS (latest quarter)Rs -3.69
EPS, 3-year averageRs -1.12
EPS, 5-year averageRs -0.82
Book value per shareRs 425.87
Sales per shareRs 185.06
Cash flow per shareRs 31.35
Free cash flow per shareRs 14.35
Efficiency
Asset turnover0.25x
Fixed asset turnover0.36x
Inventory turnover0.66x
Inventory days556 days
Debtor days84 days
Debtors turnover4.36x
Creditor days189 days
Cash conversion cycle805 days
Working capital days-60 days
Leverage
Total debtRs 3,076 Cr
Cash and bankRs 991 Cr
Net debtRs 2,085 Cr
Debt to equity0.46x
Net debt / EBITDA3.92x
Interest coverage1.09x
Current ratio (filing 2026-03-31)1.23x
Quick ratio (filing 2026-03-31)0.79x
Trade payables (filing 2026-03-31)Rs 211 Cr
Owners' fund to total sources56.05%
Debt to assets25.82%
Cash flow
Cash from Operating Activity (latest year)Rs 491 Cr
Cash from Investing Activity (latest year)Rs -245 Cr
Cash from Financing Activity (latest year)Rs 201 Cr
Net Cash Flow (latest year)Rs 447 Cr
Free cash flow (latest year)Rs 225 Cr
FCFE (approx.: FCF + change in debt)Rs 912 Cr
Sales to cash flow5.97x
Statement figures
Net sales (TTM)Rs 2,901 Cr
Net sales (latest year)Rs 2,932 Cr
Sales (latest quarter)Rs 678 Cr
Operating profit excl. other income (latest year)Rs 566 Cr
Operating profit (latest quarter)Rs 60 Cr
Other income (TTM)Rs 47 Cr
EBITDA (TTM)Rs 532 Cr
PBDT (TTM)Rs 363 Cr
Profit before tax (TTM)Rs 15 Cr
Tax (latest year)Rs 7 Cr
Net profit (TTM)Rs 16 Cr
Net profit (latest year)Rs 97 Cr
Net profit (latest quarter)Rs -58 Cr
Depreciation (TTM)Rs 348 Cr
Depreciation (latest quarter)Rs 91 Cr
Interest (TTM)Rs 169 Cr
Cost of goods sold (latest year)Rs 670 Cr
Total expenditure (latest year)Rs 2,366 Cr
Total income (latest year)Rs 2,984 Cr
Share capitalRs 31 Cr
ReservesRs 6,646 Cr
Shareholders' fundsRs 6,677 Cr
Total assetsRs 11,911 Cr
Net blockRs 8,076 Cr
Capital work in progressRs 570 Cr
InvestmentsRs 91 Cr
ReceivablesRs 673 Cr
InventoryRs 1,019 Cr
Other liabilitiesRs 2,158 Cr
Shares outstanding (crore)15.68
Ownership
Promoter holding59.32% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 145.9 is at the 96th percentile of its own 6.0-year range (median 25.1, low 4.0, high 173.0).
P/B 0.35 is at the 18th percentile (median 0.51).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodDCALNifty 50Difference
1 week-10.6%-2.8% -7.8 pts
1 month-17.3%-6.8% -10.5 pts
3 months-23.5%-7.6% -15.9 pts
6 months+15.7%+0.4% +15.3 pts
1 year-49.1%-9.9% -39.2 pts
2 years-20.3%-13.6% -6.7 pts
3 years-7.5%+14.2% -21.7 pts
5 years-28.8%+27.9% -56.7 pts
3 mutual fund schemes hold about ₹40 Cr. Over three months 2 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HSBC Flexi Cap Fund0.66%40 +25%
Bandhan BSE Healthcare Index Fund0.07%0 +27%
Motilal Oswal BSE 1000 Index Fund0.01%0

Red flags

F-score 6 of 8
lookProfit leans on other income Other income was 50% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹678 Cr -4.2% vs Jun 2025. Net loss ₹58 Cr.
Against our estimate for Jun 2026: sales -14.7%, profit -350.3% miss. Our estimate for Sep 2026: sales Rs 701 Cr, profit Rs 3 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2019-09-12 Dividend - Rs 0.20 Per Share
DateTypeWhat it says
2026-10-01Shareholder meetingVoting results of Annual General Meeting held on September 30, 2026
2026-09-30Shareholder meetingProceedings of Annual General Meeting held on September 30, 2026
2026-09-30Shareholder meetingDishman Carbogen Amcis Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026
2026-09-28AllotmentAllotment of 1500 securities pursuant to Non Convertible Securities at its meeting held on September 28, 2026
2026-09-12General UpdatesGeneral Updates
2026-09-05Shareholder meetingNotice of Annual General Meeting to be held on September 30, 2026
2026-08-31UpdatesIntimation regarding date of 19th Annual General Meeting.
2026-08-29CessationCessation of Mr Deepak Ram Chandra Mittal as Other of the company w.e.f. August 27, 2026.
2026-08-21Concall / analyst meetTranscript
2026-08-17Concall / analyst meetLink of Recording
2026-08-17AllotmentAllotment of 7500 securities pursuant to Non Convertible Securities at its meeting held on August 17, 2026
2026-08-17Investor PresentationInvestor Presentation
2026-08-14Board meeting outcomeDishman Carbogen Amcis Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-12Concall / analyst meetSchedule of meet
2026-08-12Concall / analyst meetSchedule of meet
2026-08-12Board meeting outcomeOutcome of Board Meeting held on August 12, 2026.
2026-06-30Disclosure under SEBI TakeovAdimans Technologies LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subs...
2026-06-29Press ReleaseA press release dated Jun 29, 2026, titled "PRESS RELEASE REGARDING COMPANY S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS AG., COMMISSIONS A NEW GROUN...
2026-06-22UpdatesRESPONSE TO NSE EMAIL COMMUNICATION REGARDING SUBMISSION OF FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 2026, IN MACHINE-READABLE FORM..
2026-06-20Shareholder meetingVoting results of Extraordinary General Meeting held on Jun 19, 2026
2026-06-19Shareholder meetingDishman Carbogen Amcis Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on Jun 19, 2026
2026-06-19Shareholder meetingProceedings of Extraordinary General Meeting held on Jun 19, 2026
2026-06-09AllotmentAllotment of securities pursuant to Non Convertible Securities at its meeting held on 0 ,
2026-05-27Shareholder meetingNotice of Extraordinary General Meeting to be held on Jun 19, 2026
2026-05-26General UpdatesIntimation regarding date of EGM.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Dishman Carbogen Amcis Ltd?

Dishman Carbogen Amcis Ltd (DCAL) has a market capitalisation of Rs 2,528 Cr. at the 2026-10-01 close.

What is the P/E ratio of Dishman Carbogen Amcis Ltd?

Dishman Carbogen Amcis Ltd trades at a P/E of 139 on trailing twelve-month profit, at the 2026-10-01 close.

What were Dishman Carbogen Amcis Ltd's latest quarterly results?

In the Jun 2026 quarter, Dishman Carbogen Amcis Ltd sales was Rs 678 Cr (-4.2% vs Jun 2025) with a net loss of Rs 58 Cr.

What is the 52-week high and low of Dishman Carbogen Amcis Ltd?

The 52-week high is Rs 306.00 and the 52-week low is Rs 128.50.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03